MODEL VERDICT
Guardant Health, Inc. (GH)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| May 1, 2026 | NEUTRAL | 0.14 | $87.60 | CURRENT | — |
| Apr 24, 2026 | NEUTRAL | 0.14 | $88.91 | CURRENT | — |
| Apr 17, 2026 | NEUTRAL | 0.14 | $90.36 | CURRENT | — |
| Apr 16, 2026 | NEUTRAL | 0.14 | $84.86 | CURRENT | — |
| Apr 10, 2026 | NEUTRAL | 0.14 | $78.60 | CURRENT | — |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 6 industry peers | $25.96 | -70.4% | 4% | B | Data |
| Price / Sales 6 industry peers | $33.82 | -61.4% | 3% | B | Model Driven |
| Weighted Output Blended model output | $65.51 | -25.2% | 100% | 58 | OVERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 23.26 | 16.15 | 8.54 | 61.54 | 21.97 |
| P/B Ratio | 19.72 | 15.71 | 8.35 | 46.18 | 15.45 |
| P/S Ratio | 19.09 | 13.04 | 5.07 | 43.83 | 15.59 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates GH's fair value at $65.51 vs the current price of $87.60, implying -25.2% downside potential. Model verdict: Overvalued. Confidence: 58/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $65.51 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $23.32 (P10) to $78.22 (P90), with a median of $48.89.
GH's current P/E of -26.4x compares to the industry median of 24.7x (1 peers in the group). This represents a -207.0% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
30 analysts cover GH with a consensus rating of Buy. The consensus price target is $133.14 (range: $110.00 — $175.00), implying +52.0% upside from the current price. Grade breakdown: Strong Buy (0), Buy (28), Hold (1), Sell (1), Strong Sell (0).
The model confidence score is 58/100, based on: data completeness (6), peer quality (25), historical depth (20), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for GH.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.